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Dediﬀerentiated liposarcomas may display a variety of “heterologous” lines of diﬀerentiation, including osseous, vascular, skeletal,
and/or smooth muscular. There have been six previously reported examples of leiomyosarcomas associated with high levels of
serum human chorionic gonadotropin (hCG) production, comprised of cases originating from the retroperitoneum, spermatic
cord, small intestine, and uterus. This report describes the ﬁrst example of a dediﬀerentiated liposarcoma that combined both
of the aforementioned features: extensive heterologous (leiomyosarcomatous) diﬀerentiation and β-hCG production (maximum
serum levels 1046mIU/ml, reference < 5mIU/ml). The tumor, which originated in the retroperitoneum in the region of the right
kidney, was rapidly progressive and ultimately fatal within three months of its diagnosis. In addition to characteristic morphologic
features, lipogenic and smooth muscle diﬀerentiation were conﬁrmed with immunohistochemical stains for MDM2 and smooth
muscle actin, respectively. The tumor also displayed diﬀuse immunoreactivity for β-hCG in both primary and metastatic sites.
This case further expands the clinicopathologic spectrum of lipogenic tumors.
Copyright © 2008 Michael J. Russell et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The term “tumor dediﬀerentiation” and its underlying con-
cepts, as used by contemporary surgical pathologists, are
based on the paradigm originally outlined by Dahlin and
Beabout in low-grade chondrosarcomas [1]. Tumor dedif-
ferentiation is characterized by the “emergence” of an un-
diﬀerentiated component (phenotypically unrecognizable as
to histogenesis) from an otherwise low-grade/borderline
neoplasm, with well-deﬁned morphologic demarcations be-
tween the aforementioned areas and a relatively worsened
clinical course. The phenomenon of tumor dediﬀerentiation
has subsequently been described in a wide variety of bone,
soft tissue, and epithelial and neural neoplasms [2].
Tumor dediﬀerentiation is probably most well character-
ized in lipogenic tumors. Although it had been previously
noted that well-diﬀerentiated and pleomorphic sarcomas
may be admixed [3, 4], dediﬀerentiated liposarcoma (DDLS)
was formally described by Evans in 1979 [5] .I nas e r i e so f5 5
liposarcomas, 8 cases (7 retroperitoneal, 1 spermatic cord)
were noted to display “distinct areas of well-diﬀerentiated li-
posarcoma and of cellular spindle cell or pleomorphic sar-
coma without recognizable lipogenesis” [5]. None of the
latter cases displayed a mitotic count of >5/10 high power
ﬁelds, and the cellular areas were often sharply demarcated
from the well-diﬀerentiated areas [5]. Subsequent reports
indicated that (a) dediﬀerentiation in well-DDLS is proba-
bly not anatomic site speciﬁc but time dependent [6], (b)
most retroperitoneal tumors previously classiﬁed as malig-
nant ﬁbrous histiocytomas are actually DDLS [7], (c) most
examples of DDLS present as de novo lesions rather than as
a complication of a preexisting well-diﬀerentiated liposar-
coma [8], (d) DDLS may be classiﬁed into high and low
grade depending on mitotic activity and cellularity, although2 Sarcoma
the prognostic signiﬁcance of this gradation is unclear
[8–11].
As with their clinical spectrum, the pathologic spectrum
of DDLS has been similarly expanded. Newer morphologic
observations have included a potentially poorly deﬁned in-
terface between the DDLS and its well-diﬀerentiated compo-
nent [8], whorled, meningothelial-like structures [8, 12–14],
a prominent inﬂammatory component [9], a micronodular
growth pattern [9], a hemangiopericytomatous vascular pat-
tern [8, 9], and heterologous diﬀerentiation [8, 9, 14–20].
Chondroid metaplasia, rhabdomyosarcomatous, and
smoothmusculardiﬀerentiationhavebeendescribedinwell-
diﬀerentiated and myxoid liposarcomas [2, 21–24]; the term
lipoleiomyosarcoma is commonly used for morphologic ad-
mixtures of well-diﬀerentiated liposarcoma and leiomyosar-
coma. [23]. However, the probability for histologic misclas-
siﬁcation is highest when high-grade DDLS displays heterol-
ogous diﬀerentiation [4, 5, 8, 9, 11–16]. Lines of heterolo-
gous diﬀerentiation that have been described in DDLS in-
clude leiomyosarcomatous, osteochondrosarcomatous, an-
giosarcomatous,andrhabdomyosarcomatousanddonotap-
pear to have independent prognostic signiﬁcance [4, 5, 8, 9,
11–16, 25]
This report describes an example of a retroperitoneal
DDLS with extensive leiomyosarcomatous diﬀerentiation
that was accompanied by high levels of serum beta-human
chorionic gonadotropin (β-hCG). This composite of ﬁnd-
ings has, to our knowledge, not been previously reported.
2. CLINICAL HISTORY
In 2006, a 67-year-old Caucasian female presented with
episodic right upper quadrant abdominal pain and associ-
ated nausea. Her past medical history was signiﬁcant for
an inﬁltrating ductal breast carcinoma (treated with radi-
cal mastectomy followed by 4 cycles of adriamycin in 1999),
a stable plasma cell dyscrasia (multiple myeloma diagnosed
by a bone marrow biopsy and serum protein electrophore-
sis in 2003, treated with high dose chemotherapy, and which
was associated with a mild normocytic anemia in the en-
suing period), and a hysterectomy/salpingo-oophorectomy
(for benign indications). A computed tomographic (CT)
scan of the abdomen showed a heterogeneously enhancing
mass extending from the inferior right renal pole exophyti-
cally, with signiﬁcant associated inﬂammatory changes and
some peripheral coarse calciﬁcations. Portocaval and mesen-
teric adenopathy were also present. Serum levels of alpha-
fetoprotein, carcinoembryonic antigen, CA15-3, and CA27-
29 were within normal limits. Notably, a serum β-hCG,
requested inadvertently, measured 210.3mIU/ml (reference
value for nongestational adults <5mIU/L).
Given the high suspicion for a renal cell carcinoma, the
right kidney was resected as well as all grossly identiﬁable
perinephric tumor. Intraoperatively, the mass was noted to
be prominently adhered to the surrounding retroperitoneal
tissue. A follow-up serum β-hCG, which was measured 26
days after the ﬁrst measurement and 25 days after her sur-
gical procedure, measured 1046mIU/ml. An abdominal CT
scan performed shortly thereafter revealed multiple hypo-
dense liver masses measuring up to 5cm, with an increase in
the aforementioned portocaval adenopathy. Biopsy of one of
the hepatic masses conﬁrmed the presence of metastatic dis-
ease. The patient declined further therapeutic measures and
expired 2 months later. An autopsy was not performed.
3. MATERIALS AND METHODS
Twenty sections of the retroperitoneal mass were routinely
processed for microscopic evaluation. The liver biopsy was
similarly processed. For immunohistochemistry, 4-5μ-thick
sections were cut and mounted on a glass slide, deparaf-
ﬁnized and rehydrated. Appropriate negative and positive
controls were included. All assays were carried out in an
Axiom 36 autostainer (Lab Vision Corporation, Fremont,
Calif, USA). The following markers were evaluated in the
liver biopsy and a representative section of the retroperi-
toneal mass, in parallel: β-hCG (clone CG04+CG05, predi-
luted, Lab Vision), keratin cocktail comprised of clones
AE1/AE3 (Signet Corporation, Dedham, Mass, USA) and
LP34 (DakoCytomation, Carpinteria, Calif, USA), dilution
1:200, Smooth muscle actin: SMA (clone1A4, prediluted,
Lab Vision), Estrogen receptor-alpha: ER-alpha (clone ID5,
dilution 1:50, DakoCytomation), Progesterone receptor:
PR (clone PgR 636, prediluted, DakoCytomation), Desmin
(clone D33, prediluted, Lab Vision), Epithelial membrane
antigen (EMA) (clone E29, prediluted, ThermoFisher Sci-
entiﬁc, Fremont, Calif, USA), MDM2 (clone IF2, dilution
1:100, Lab Vision), and placental-like alkaline phosphatase:




gregate 21 × 10 × 7cm. Sectioning revealed an inferior pole
massmeasuring9.5cminmaximumdimension,whichcom-
pressedanddistortedtherenalpelvisandthetissueinthisre-
gion. The cut surface of the mass was largely ﬁrm and solid,
tan-white in color, with hemorrhagic areas but no grossly
identiﬁable necrosis.
4.2. Morphologicfeatures
The retroperitoneal tumor displayed the characteristic mor-
phologic features of DDLS. In the well-diﬀerentiated com-
ponent, large coarse ﬁbrotic bands were observed irregularly,
coursing through lobules of well-diﬀerentiated adipocytes.
Withintheﬁbrousbands,theperivascularregionsandwithin
the adipocytic lobules were scattered cells with large irregu-
lar and hyperchromatic nuclei (Figure 1). The mitotic index
in these regions was low. The dediﬀerentiated component
comprised approximately 80% of the tumor mass. The in-
terface between the well-diﬀerentiated and dediﬀerentiated
components was variable: the interface was well demarcated
in some regions (Figure 2), and highly irregular/inﬁltrative
in others. The central portion of the mass was necrotic, while
the surrounding areas, comprising approximately 10% of the
mass were hypocellular and hyalinized. However, atypicalMichael J. Russell et al. 3
Figure 1:Well-diﬀerentiated component oftheliposarcoma, show-
ing atypical cells with nucleomegaly and hyperchromasia scattered
within mature adipocytes and intervening ﬁbrous septae.
Figure 2: The interface between the well-diﬀerentiated and dedif-
ferentiated components.
Figure 3: Cellular areas of the dediﬀerentiated component.
cells well still recognizable in these regions. The remainder
of the mass displayed a spectrum of pathologic changes with
respect to cellularity, mitotic activity and atypia. Nonethe-
less,thetumorwaspredominantlyahigh-gradepleomorphic
spindle cell sarcoma. In the most hypocellular regions, scat-
tered atypical cells were clearly evident in a hyalinized back-
groundanddisplayedamaximummitoticindexof11MF/10
high power ﬁelds. Other areas were signiﬁcantly more cel-
Figure 4: Some areas of the dediﬀerentiated component were com-
prised of cells with varying amounts of eosinophilic cytoplasm.
lular, and were comprised of cells with hyperchromatic nu-
clei arranged in vague fascicles (Figure 3). These areas dis-
playedthehighestmitoticactivity(maximum36MF/10high
power ﬁelds). Constituent cell displayed variable amounts
of eosinophilic cytoplasm (Figure 4). The growth pattern of
the tumor relative to the adjacent kidney was largely to dis-
placeit.However,therewereareaswherethetumorappeared
to inﬁltrate in an interstitial pattern, with glomeruli encir-
cled by tumor cells. The portions of the tumor not com-
prised of spindle cells were comprised of nondescript pleo-
morphic cells. Lipoblasts were evident throughout the tu-
mor and there were no morphologically-recognizable syncy-
tiotrophoblasts. The portion of the liver mass that was sam-
pled was comprised predominantly of spindle cells as de-
scribed above.
4.3. Immunophenotypicfeatures
The retroperitoneal tumor and liver mass displayed an
identical immunoproﬁle, consistent with the latter being a
metastatic deposit from the former. Both displayed diﬀuse
immunoreactivity for desmin, SMA, β-hCG (Figure 5), and
MDM2 (Figure 6) .T h et u m o r sw e r en e g a t i v ef o rE R ,P R ,
EMA, PLAP, and keratins.
5. DISCUSSION
hCG, a glycoprotein with a molecular weight of 38000, is
comprised of two subunits—α and β—that are noncova-
lently bound to form a heterodimer [26, 27]. The α subunit
of hCG is identical to the α subunits of luteining hormone,
follicle stimulating hormone, and thyrotropin; the β subunit
therefore provides hormonal speciﬁcity [26, 27]. The mea-
surement of serum β-hCG has its greatest clinical utility in
thediagnosisofgestation,congenitaldisorders,andgermcell
neoplasia. However, it has long been recognized that a wide
variety of other nongerm cell neoplasms, predominantly car-
cinomas, may be associated with elevated serum β-hCG, in
which it appears to function as an autocrine growth fac-
tor by inhibiting apoptosis [28, 29]. The expression of hCG
has also been found to be an adverse prognostic factor in
some speciﬁc histotypes such as small cell lung carcinoma,4 Sarcoma
Figure 5: The tumor cells displayed diﬀuse immunoreactivity for
β-hCG.
Figure 6: The tumor cells displayed diﬀuse immunoreactivity for
MDM2.
transitional cell carcinoma of the urinary bladder, and pro-
static and colorectal adenocarcinoma [30–33]. Rare exam-
ples of osteosarcoma [28, 34–36], chondrosarcoma [37], and
leiomyosarcoma [38–43] have been associated with elevated
serum β-hCG. Amongst the six previously reported exam-
ples of β-hCG-producing leiomyosarcomas, two originated
in the retroperitoneum [42, 43], two in the spermatic cord
[39, 41], one in the uterus [40], and one in the small intes-
tine [38]. Notably, ﬁve of the six patients succumbed to their
disease within one year of their diagnoses. However, the sar-
comas were high grade; thus the independent prognostic sig-
niﬁcance of β-hCG remains unclear.
In the present case, a DDLS with extensive leiomyosarco-
matous diﬀerentiation was associated with β-hCG produc-
tion, as evidenced by demonstration of β-hCG expression
in the tumor and its metastatic deposit by immunohisto-
chemistry, and an elevation of serum β-hCG that was tem-
porally related to tumor progression. The diagnostic utility
of MDM2, a recently described marker reportedly useful for
distinguishing DDLS from their histologic mimics [44], was
conﬁrmed, as this marker helped to establish, in addition to
morphologic features, underlying lipogenic diﬀerentation.
β-hCG production by DDLS has not been previously re-
ported toourknowledgeandispresumedtorepresent“aber-
rant”diﬀerentiationinahigh-gradetumor.Nonetheless,this
ﬁnding expands the clinicopathologic spectrum of lipogenic
tumors in general. Furthermore, it suggests that liposarcoma
should be a diﬀerential consideration when elevated serum
β-hCG is associated with a radiographic mass lesion, espe-
cially when the mass is retroperitoneal.
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